Manufacturer
INTAS PHARM LTD
Contents
Cytarabine
Indication
Alone or in combination w/ other chemotherapeutic agents for induction of leukaemia remission, particularly for acute myeloid leukaemia in adult & childn. Remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia & erythroleukaemia; treatment & maintenance therapy of meningeal leukaemia & neoplasms.
Instruction
Monotherapy in induction remission & maintenance in adult & childn w/ acute myelocytic leukaemia, acute lymphocytic leukaemia 200 mg/m2 daily by continuous IV infusion over 24 hr for 5 days, repeat course approx every 2 wk. Intrathecal use in meningeal leukaemia 30 mg/m2 every 4 days until CSF findings were normal, followed by 1 additional treatment. Dose range: 5-75 mg/m2 once daily for 4 days to once every 4 days.
Drug interaction
Substantially reduced digoxin GI absorption. Antagonized activity of gentamicin against Klebsiella pneumoniae. Antagonized activity of flucytosine.
Malaysia
